Hyphens Pharma (SGX:1J5) completed the proposed acquisition of tranche 2 sale shares of Ardence Pharma for a total consideration of 10.9 million ringgit, according to a filing with the Singapore Exchange on Friday.
Following the completion of the tranche 2, the company now has an 82% stake in Ardence, a Malaysia-based boutique pharmaceutical company specializing in aesthetic medicine.
In an earlier filing, the company, through its unit Hyphens Pharma, agreed to acquire the remaining 58% stake in Ardence Pharma in three tranches.
Under first tranche, the pharmaceutical company acquired 23% of Ardence Pharma for 6.4 million Malaysian ringgit.
In the second and third tranches, Hyphens Pharma will acquire 17% and 18% of Ardence Pharma, respectively, at an amount mutually agreed between the parties involved.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。